Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
- Revenue in CHF (TTM)165.51m
- Net income in CHF50.16m
- Incorporated--
- Employees332.00
- LocationCosmo Pharmaceuticals NVRiverside IISir John Rogerson's Quay, Dublin 2DUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttps://www.cosmopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S | 837.18m | 297.21m | 1.90bn | 1.74k | 6.46 | 1.17 | 4.97 | 2.27 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| HUTCHMED (China) Ltd | 463.03m | 358.99m | 1.95bn | 1.78k | 5.42 | 2.06 | 5.28 | 4.20 | 4.19 | 4.19 | 5.40 | 11.03 | 0.3966 | 7.09 | 3.86 | 2,601,352.00 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Pfizer Ltd | 209.55m | 72.06m | 1.95bn | 1.60k | 27.13 | -- | 25.37 | 9.33 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Dermapharm Holding SE | 1.05bn | 105.39m | 1.96bn | 3.55k | 18.65 | 3.33 | 11.39 | 1.86 | 2.15 | 2.15 | 21.54 | 12.06 | 0.5472 | 1.13 | 9.18 | 321,361.20 | 5.39 | 7.72 | 6.40 | 9.04 | 66.57 | 63.64 | 9.85 | 11.81 | 1.04 | 4.88 | 0.61 | 52.26 | 4.00 | 11.00 | 82.44 | 8.07 | -3.81 | -- |
| Tonghua Dongbao Pharmaceutical Co Ltd | 307.33m | 137.43m | 1.97bn | 3.41k | 14.32 | 2.47 | -- | 6.42 | 0.6271 | 0.6271 | 1.40 | 3.64 | 0.3589 | 1.05 | 5.11 | 803,924.60 | 15.84 | 14.89 | 17.08 | 15.68 | 71.05 | 78.86 | 44.15 | 35.26 | 3.49 | -- | 0.0988 | 50.60 | -34.66 | -6.27 | -103.66 | -- | 14.17 | 4.56 |
| Cosmo Pharmaceuticals NV | 165.51m | 50.16m | 1.99bn | 332.00 | 37.55 | 4.32 | 32.96 | 12.00 | 3.02 | 3.02 | 10.16 | 26.22 | 0.292 | 3.64 | 8.05 | 514,335.00 | 8.83 | 4.65 | 9.60 | 5.15 | 73.79 | 68.39 | 30.23 | 26.16 | 3.59 | -- | 0.0058 | 49.72 | 187.55 | 33.68 | 1,335.61 | -- | -20.06 | -- |
| Jinyu Bio-Technology Co Ltd | 148.77m | 11.30m | 2.00bn | 1.74k | 225.77 | 3.26 | -- | 13.43 | 0.071 | 0.071 | 1.27 | 4.92 | 0.1946 | 2.45 | 1.89 | 762,676.30 | 1.37 | 4.31 | 1.56 | 5.06 | 50.46 | 57.76 | 7.02 | 17.99 | 3.09 | -- | 0.0029 | 36.89 | -21.45 | 2.19 | -61.57 | -13.19 | -21.84 | -12.94 |
| Shandong Buchang Pharmaceuticals Co Ltd | 1.23bn | 186.39k | 2.02bn | 7.69k | 2,504.40 | 1.70 | -- | 1.64 | 0.0068 | 0.0068 | 10.34 | 10.03 | 0.5519 | 0.9196 | 13.73 | 1,425,409.00 | -0.6503 | 0.8521 | -0.9366 | 1.25 | 62.31 | 70.57 | -1.18 | 1.32 | 0.4929 | 3.23 | 0.2758 | 157.32 | -16.91 | -5.04 | -273.62 | -- | -21.53 | -- |
| Apellis Pharmaceuticals Inc | 771.76m | 17.21m | 2.06bn | 733.00 | 169.74 | 7.17 | 111.89 | 2.67 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 531.63k | 3.03% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Jan 2026 | 333.03k | 1.90% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 330.83k | 1.89% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 213.65k | 1.22% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 134.92k | 0.77% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 124.44k | 0.71% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 103.67k | 0.59% |
| Valiant Bank AGas of 31 Dec 2025 | 78.78k | 0.45% |
| Swiss Rock Asset Management AGas of 31 Jan 2026 | 54.02k | 0.31% |
| LLB Asset Management AGas of 31 Dec 2025 | 49.73k | 0.28% |
